In this context, TRPV1 was also found to contribute to adverse pain-mediating effects in an in vitro model of psoralen UVA (PUVA) therapy used to treat vitiligo, psoriasis, eczema and mycosis fungoides [189]. Here, TRPV1 is linked to psoriasis.